Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.10 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 25 Parkinson's papers of 348 | 0.57 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 2672
Sealed predictions
- SGCE in dopamine neurons, braak+0.63 (p 0.067) → -0.20 (p 0.613)receipt 2679
Swarm cases
receipt 2679: SGCE in dopamine neurons, braak
- power
- full sample +0.23 (p 0.355, n 18), 95% CI -0.26 to +0.63. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.24 (p 0.332, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.28 (p 0.254, n 18). could be the mix.
- skeptic
- leave-one-out range +0.14 to +0.38, sign flips 0; without severely affected donors +0.23 (p 0.355, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.71 (p 0.0011, n 18) vs +0.23 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SGCE in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up SGCE · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.13 p 0.657 (needs p < 6.8e-4)
Receipts
loading the receipts